Document is current

Article History

Received: 22 April 2025

Accepted: 30 May 2025

First Online: 22 June 2025

Declarations

:

: Jonathan A. Bernstein reports grants from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin, Intellia, Astria, Aretrea, Pharvaris, Blueprint Medicines, Cogent, Telios, Yuhan, Evoimmune, Incyte/Escient, Jasper, Eli Lilly, Allergy Therapeutics, and Genentech outside the submitted work; personal fees from Novartis, AstraZeneca, Sanofi‑Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin, and Genentech outside the submitted work. Tonya Winders receives funds from unbranded disease awareness and education from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche, and Genentech outside the submitted work. Jessica McCarthy is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, and reports holding shares of Novartis Pharma AG. Pallavi Saraswat is an employee of Novartis Healthcare Pvt Ltd, Hyderabad, India, and reports holding shares of Novartis Pharma AG. Nadine Chapman-Rothe is an employee of Novartis Pharma AG, Basel, Switzerland, and reports holding shares of Novartis Pharma AG. Tara Raftery is an employee of Novartis Ireland Ltd, Dublin, Ireland, and reports holding shares of Novartis Pharma AG. Karsten Weller reports grants from Novartis, Sanofi, and Takeda outside the submitted work and personal fees from BioCryst, BioMarin, CSL Behring, Novartis, Moxie, and Takeda outside the submitted work.

: This study was conducted in accordance with legal and regulatory requirements and fulfilled the criteria of the “European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study” and followed the “ENCePP Code of Conduct,” as previously described []. All participants of the survey provided written informed consent forms, approved by the corresponding institutional review board/ethics committee (IRB/IEC) and in accordance with the Declaration of Helsinki and other relevant regulatory requirements. An exemption from ongoing oversight was obtained from the Pearl IRB, who reviewed and granted international approval of an exemption []..